Cardiac amyloidosis was once considered untreatable. Now, we have effective treatments, less invasive diagnostic tests, and a growing body of research in this complex disease.
New AHA guidelines highlight the benefits of SGLT2i medications for patients with heart failure and advances in diagnosing and treating ATTR amyloidosis.
A new, FDA-approved four-drug combo for AL amyloidosis is improving longevity and quality of life dramatically. Ankit Kansagra, M.D., discusses how the medication and a multidisciplinary team of experts can give patients longer, healthier lives.
